{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:11:57Z","timestamp":1787962317851,"version":"build-2784847793"},"reference-count":303,"publisher":"National Institute for Health and Care Research","issue":"66","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000276","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["06\/303\/84"],"award-info":[{"award-number":["06\/303\/84"]}],"id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"Background<\/jats:title>Rheumatoid arthritis (RA) is initially treated with methotrexate and other disease-modifying antirheumatic drugs (DMARDs). Active RA patients who fail such treatments can receive tumour necrosis factor inhibitors (TNFis), which are effective but expensive.<\/jats:p><\/jats:sec>Objective<\/jats:title>We assessed whether or not combination DMARDs (cDMARDs) give equivalent clinical benefits at lower costs in RA patients eligible for TNFis.<\/jats:p><\/jats:sec>Design<\/jats:title>An open-label, 12-month, pragmatic, randomised, multicentre, two-arm trial [Tumour necrosis factor inhibitors Against Combination Intensive Therapy (TACIT)] compared these treatment strategies. We then systematically reviewed all comparable published trials.<\/jats:p><\/jats:sec>Setting<\/jats:title>The TACIT trial involved 24 English rheumatology clinics.<\/jats:p><\/jats:sec>Participants<\/jats:title>Active RA patients eligible for TNFis.<\/jats:p><\/jats:sec>Interventions<\/jats:title>The TACIT trial compared cDMARDs with TNFis plus methotrexate or another DMARD; 6-month non-responders received (a) TNFis if in the cDMARD group; and (b) a second TNFi if in the TNFi group.<\/jats:p><\/jats:sec>Main outcome measures<\/jats:title>The Heath Assessment Questionnaire (HAQ) was the primary outcome measure. The European Quality of Life-5 Dimensions (EQ-5D), joint damage, Disease Activity Score for 28 Joints (DAS28), withdrawals and adverse effects were secondary outcome measures. Economic evaluation linked costs, HAQ changes and quality-adjusted life-years (QALYs).<\/jats:p><\/jats:sec>Results<\/jats:title>In total, 432 patients were screened; 104 started on cDMARDs and 101 started on TNFis. The initial demographic and disease assessments were similar between the groups. In total, 16 patients were lost to follow-up (nine in the cDMARD group, seven in the TNFi group) and 42 discontinued their intervention but were followed up (23 in the cDMARD group and 19 in the TNFi group). Intention-to-treat analysis with multiple imputation methods used for missing data showed greater 12-month HAQ score reductions with initial cDMARDs than with initial TNFis [adjusted linear regression coefficient 0.15, 95% confidence interval (CI) \u22120.003 to 0.31;p<\/jats:italic>\u2009=\u20090.046]. Increases in 12-month EQ-5D scores were greater with initial cDMARDs (adjusted linear regression coefficient \u22120.11, 95% CI \u22120.18 to \u22120.03;p<\/jats:italic>\u2009=\u20090.009) whereas 6-month changes in HAQ and EQ-5D scores and 6- and 12-month changes in joint damage were similar between the initial cDMARD group and the initial TNFi group. Longitudinal analyses (adjusted general estimating equations) showed that the DAS28 was lower in the initial TNFi group in the first 6 months (coefficient \u22120.63, 95% CI \u22120.93 to \u22120.34;p<\/jats:italic>\u2009<\u20090.001) but there were no differences between the groups in months 6\u201312. In total, 36 patients in the initial cDMARD group and 44 in the initial TNFi group achieved DAS28 remission. The onset of remission did not differ between groups (p<\/jats:italic>\u2009=\u20090.085 on log-rank test). In total, 10 patients in the initial cDMARD group and 18 in the initial TNFi group experienced serious adverse events; stopping therapy because of toxicity occurred in 10 and six patients respectively. Economic evaluation showed that the cDMARD group had similar or better QALY outcomes than TNFi with significantly lower costs at 6 and 12 months. In the systematic reviews we identified 32 trials (including 20\u20131049 patients) on early RA and 19 trials (including 40\u2013982 patients) on established RA that compared (1) cDMARDs with DMARD monotherapy; (2) TNFis\/methotrexate with methotrexate monotherapy; and (3) cDMARDs with TNFis\/methotrexate. They showed that cDMARDs and TNFis had similar efficacies and toxicities.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Active RA patients who have failed methotrexate and another DMARD achieve equivalent clinical benefits at a lower cost from starting cDMARDs or from starting TNFis (reserving TNFis for non-responders). Only a minority of patients achieve sustained remission with cDMARDs or TNFis; new strategies are needed to maximise the frequency of remission.<\/jats:p><\/jats:sec>Trial registration<\/jats:title>Current Control Trials ISRCTN37438295.<\/jats:p><\/jats:sec>Funding<\/jats:title>This project was funded by the National Institute for Health Research Health Technology Assessment programme and will be published in full inHealth Technology Assessment<\/jats:italic>; Vol. 18, No. 66. See the NIHR Journals Library website for further project information.<\/jats:p><\/jats:sec>","DOI":"10.3310\/hta18660","type":"journal-article","created":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T09:05:06Z","timestamp":1414659906000},"page":"1-164","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Randomised controlled trial of Tumour necrosis factor inhibitors Against Combination Intensive Therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews"],"prefix":"10.3310","volume":"18","clinical-trial-number":[{"clinical-trial-number":"isrctn37438295","registry":"10.18810\/isrctn","type":"results"}],"author":[{"given":"David L","family":"Scott","sequence":"first","affiliation":[{"name":"Department of Rheumatology, King\u2019s College London School of Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fowzia","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, King\u2019s College London School of Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vern","family":"Farewell","sequence":"additional","affiliation":[{"name":"MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan G","family":"O\u2019Keeffe","sequence":"additional","affiliation":[{"name":"MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, King\u2019s College London School of Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Walker","sequence":"additional","affiliation":[{"name":"Musculoskeletal Unit, Freeman Hospital, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Heslin","sequence":"additional","affiliation":[{"name":"Centre for the Economics of Mental and Physical Health, Institute of Psychiatry, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Patel","sequence":"additional","affiliation":[{"name":"Centre for the Economics of Mental and Physical Health, Institute of Psychiatry, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Kingsley","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, King\u2019s College London School of Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2014,10]]},"reference":[{"key":"key2014102715194279_ref1-bib1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"key2014102715194279_ref1-bib2","doi-asserted-by":"publisher","first-page":"c6942","DOI":"10.1136\/bmj.c6942","article-title":"Recent advances in the management of rheumatoid arthritis","volume":"341","author":"Klarenbeek","year":"2010","journal-title":"BMJ"},{"key":"key2014102715194279_ref1-bib3","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"key2014102715194279_ref1-bib4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/1529-0131(195902)2:1<16::AID-ART1780020104>3.0.CO;2-9","article-title":"1958 revision of diagnostic criteria for rheumatoid arthritis","volume":"2","author":"Ropes","year":"1959","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib6","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"The 2010 American College of Rheumatology\/European League against Rheumatism classification criteria for rheumatoid arthritis","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib7","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.berh.2007.05.006","article-title":"The course of established rheumatoid arthritis","volume":"21","author":"Scott","year":"2007","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"key2014102715194279_ref1-bib8","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.berh.2007.05.007","article-title":"Extra-articular manifestations and complications of rheumatoid arthritis","volume":"21","author":"Young","year":"2007","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"key2014102715194279_ref1-bib9","first-page":"S35","article-title":"Mortality in rheumatoid arthritis: 2008 update","volume":"26","author":"Sokka","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"key2014102715194279_ref1-bib10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/art.24281","article-title":"Current risk factors for work disability associated with rheumatoid arthritis: recent data from a US national cohort","volume":"61","author":"Allaire","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib11","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1136\/ard.2008.094128","article-title":"Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing","volume":"68","author":"Smolen","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib12","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.berh.2007.06.002","article-title":"Comorbidities in rheumatoid arthritis","volume":"21","author":"Michaud","year":"2007","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"key2014102715194279_ref1-bib13","first-page":"S22","article-title":"Disease activity measures for rheumatoid arthritis","volume":"25","author":"Dougados","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"key2014102715194279_ref1-bib14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.7326\/0003-4819-146-11-200706050-00008","article-title":"Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis","volume":"146","author":"Nishimura","year":"2007","journal-title":"Ann Intern Med"},{"key":"key2014102715194279_ref1-bib15","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1002\/art.24716","article-title":"Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis","volume":"60","author":"van der Linden","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib16","doi-asserted-by":"publisher","first-page":"456","DOI":"10.7326\/0003-4819-152-7-201004060-00010","article-title":"Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis","volume":"152","author":"Whiting","year":"2010","journal-title":"Ann Intern Med"},{"key":"key2014102715194279_ref1-bib17","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.rdc.2009.10.005","article-title":"Radiographic measures to assess patients with rheumatoid arthritis: advantages and limitations","volume":"35","author":"Yazici","year":"2009","journal-title":"Rheum Dis Clin North Am"},{"key":"key2014102715194279_ref1-bib18","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.2214\/AJR.07.2548","article-title":"Early rheumatoid arthritis: a review of MRI and sonographic findings","volume":"189","author":"Boutry","year":"2007","journal-title":"Am J Roentgenol"},{"key":"key2014102715194279_ref1-bib19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1749-6632.2009.04392.x","article-title":"Quantifying disease activity and damage by imaging in rheumatoid arthritis and osteoarthritis","volume":"1154","author":"Kubassova","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"key2014102715194279_ref1-bib20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.rdc.2012.05.001","article-title":"Genetics of rheumatoid arthritis: an impressionist perspective","volume":"38","author":"Jacob","year":"2012","journal-title":"Rheum Dis Clin North Am"},{"key":"key2014102715194279_ref1-bib21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/ard.2008.096487","article-title":"Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies","volume":"69","author":"Sugiyama","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrrheum.2011.76","article-title":"Anti-CCP antibodies: the past, the present and the future","volume":"7","author":"van Venrooij","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"key2014102715194279_ref1-bib23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0049-0172(00)80017-7","article-title":"The costs of rheumatoid arthritis: an international long-term view","volume":"29","author":"Pugner","year":"2000","journal-title":"Semin Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.berh.2008.11.005","article-title":"The economics of treatment in early rheumatoid arthritis","volume":"23","author":"Bansback","year":"2009","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"key2014102715194279_ref1-bib25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/pst.368","article-title":"The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation","volume":"8","author":"Nixon","year":"2009","journal-title":"Pharm Stat"},{"key":"key2014102715194279_ref1-bib26","volume-title":"Services for People with Rheumatoid Arthritis","author":"","year":"2009"},{"key":"key2014102715194279_ref1-bib27","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.berh.2007.06.001","article-title":"Established rheumatoid arthritis: clinical assessments","volume":"21","author":"van Riel","year":"2007","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"key2014102715194279_ref1-bib28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3899\/jrheum.090129","article-title":"Patient-driven outcomes in rheumatoid arthritis","volume":"82","author":"Wells","year":"2009","journal-title":"J Rheumatol Suppl"},{"key":"key2014102715194279_ref1-bib29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.rdc.2012.04.005","article-title":"Disease activity assessment and patient-reported outcomes in patients with early rheumatoid arthritis","volume":"38","author":"Sokka","year":"2012","journal-title":"Rheum Dis Clin North Am"},{"key":"key2014102715194279_ref1-bib30","first-page":"S14","article-title":"The Health Assessment Questionnaire (HAQ)","volume":"23","author":"Bruce","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"key2014102715194279_ref1-bib31","first-page":"1896","article-title":"Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients","volume":"31","author":"Wolfe","year":"2004","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/msc.171","article-title":"Psychological well-being in rheumatoid arthritis: a review of the literature","volume":"8","author":"Gettings","year":"2010","journal-title":"Musculoskeletal Care"},{"key":"key2014102715194279_ref1-bib33","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","article-title":"The Disease Activity Score and the EULAR response criteria","volume":"35","author":"Fransen","year":"2009","journal-title":"Rheum Dis Clin North Am"},{"key":"key2014102715194279_ref1-bib34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.rdc.2009.10.006","article-title":"The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical care","volume":"35","author":"Aletaha","year":"2009","journal-title":"Rheum Dis Clin North Am"},{"key":"key2014102715194279_ref1-bib35","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib36","doi-asserted-by":"publisher","first-page":"R155","DOI":"10.1186\/ar2832","article-title":"The prognostic value of baseline erosions in undifferentiated arthritis","volume":"11","author":"Thabet","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"key2014102715194279_ref1-bib37","first-page":"55","article-title":"Radiological progression in established rheumatoid arthritis","volume":"69","author":"Scott","year":"2004","journal-title":"J Rheumatol Suppl"},{"key":"key2014102715194279_ref1-bib38","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/rheumatology\/keq437","article-title":"Comparison of the efficacy of sonography, magnetic resonance imaging and conventional radiography for the detection of bone erosions in rheumatoid arthritis patients: a systematic review and meta-analysis","volume":"50","author":"Baillet","year":"2011","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/rheumatology\/kes122","article-title":"Developing an effective treatment algorithm for rheumatoid arthritis","volume":"51","author":"Keystone","year":"2012","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib40","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/annrheumdis-2011-200618","article-title":"Defining remission in rheumatoid arthritis","volume":"71","author":"Felson","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib41","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3899\/jrheum.091131","article-title":"Remission in early rheumatoid arthritis","volume":"37","author":"Ma","year":"2010","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib42","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1136\/annrheumdis-2012-201821","article-title":"Performance of the 2011 ACR\/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis","volume":"72","author":"Thiele","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib43","doi-asserted-by":"publisher","first-page":"iii56","DOI":"10.1136\/ard.2007.078360","article-title":"Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility","volume":"66","author":"Bakker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib44","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/clpt.2011.278","article-title":"Biologics-based therapy for the treatment of rheumatoid arthritis","volume":"91","author":"Scott","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"key2014102715194279_ref1-bib45","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2012-202333","article-title":"Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also \u2018disconnect\u2019 disease activity and damage in rheumatoid arthritis","volume":"72","author":"Boers","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib46","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrrheum.2012.111","article-title":"Rheumatoid arthritis: defining remission in patients with RA in clinical practice","volume":"8","author":"Westhovens","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"key2014102715194279_ref1-bib47","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.berh.2011.10.006","article-title":"The use of conventional disease-modifying anti-rheumatic drugs in established RA","volume":"25","author":"Jurgens","year":"2011","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"key2014102715194279_ref1-bib48","first-page":"590","article-title":"Leflunomide Rheumatoid Arthritis Investigators Groups. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis","volume":"32","author":"Strand","year":"2005","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib49","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/art.22353","article-title":"Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis","volume":"55","author":"Finckh","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib50","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1136\/ard.2008.094474","article-title":"Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib51","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/rheumatology\/keh003","article-title":"A survey of British rheumatologists\u2019 DMARD preferences for rheumatoid arthritis","volume":"43","author":"Jobanputra","year":"2004","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib52","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/ard.2009.127225","article-title":"Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis","volume":"69","author":"Gaujoux-Viala","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib53","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.jbspin.2011.01.010","article-title":"Optimizing methotrexate therapy in rheumatoid arthritis: a systematic literature review","volume":"78","author":"Mouterde","year":"2011","journal-title":"Joint Bone Spine"},{"key":"key2014102715194279_ref1-bib54","first-page":"CD000958","article-title":"Sulfasalazine for rheumatoid arthritis","volume":"2","author":"Suarez-Almazor","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"key2014102715194279_ref1-bib55","first-page":"1182","article-title":"Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis","volume":"30","author":"Osiri","year":"2003","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib56","first-page":"CD000959","article-title":"Antimalarials for treating rheumatoid arthritis","volume":"4","author":"Suarez-Almazor","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"key2014102715194279_ref1-bib57","first-page":"CD000520","article-title":"Injectable gold for rheumatoid arthritis","volume":"2","author":"Clark","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"key2014102715194279_ref1-bib58","first-page":"CD001461","article-title":"Azathioprine for treating rheumatoid arthritis","volume":"4","author":"Suarez-Almazor","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"key2014102715194279_ref1-bib59","first-page":"CD000189","article-title":"Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis","volume":"3","author":"Gotzsche","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"key2014102715194279_ref1-bib60","first-page":"CD006356","article-title":"Effects of glucocorticoids on radiological progression in rheumatoid arthritis","volume":"1","author":"Kirwan","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"key2014102715194279_ref1-bib61","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1136\/ard.2009.127332","article-title":"Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis","volume":"69","author":"Gorter","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib62","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJM198110223051710","article-title":"Treating intractable rheumatoid arthritis","volume":"305","author":"McCarty","year":"1981","journal-title":"N Engl J Med"},{"key":"key2014102715194279_ref1-bib63","first-page":"645","article-title":"Combination therapy in rheumatoid arthritis \u2013 no benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy","volume":"20","author":"Porter","year":"1993","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib64","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/art.1780350802","article-title":"Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial","volume":"35","author":"Willkens","year":"1992","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib65","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1002\/art.1780371012","article-title":"The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis","volume":"37","author":"Felson","year":"1994","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib66","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJM199507203330301","article-title":"Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate\u2013Cyclosporine Combination Study Group","volume":"333","author":"Tugwell","year":"1995","journal-title":"N Engl J Med"},{"key":"key2014102715194279_ref1-bib67","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJM199605163342002","article-title":"Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications","volume":"334","author":"O\u2019Dell","year":"1996","journal-title":"N Engl J Med"},{"key":"key2014102715194279_ref1-bib68","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","article-title":"Randomised comparison of combined step-down prednisolone, methotrexate and suphasalazine with sulphasalazine alone in early rheumatoid arthritis","volume":"350","author":"Boers","year":"1997","journal-title":"Lancet"},{"key":"key2014102715194279_ref1-bib69","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/rheumatology\/ker355","article-title":"Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial","volume":"51","author":"van Eijk","year":"2012","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib70","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1093\/rheumatology\/kei031","article-title":"A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal","volume":"44","author":"Choy","year":"2005","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib71","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/rheumatology\/ken406","article-title":"Early Rheumatoid Arthritis Network. Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: the ERAN cohort","volume":"48","author":"Kiely","year":"2009","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib72","doi-asserted-by":"publisher","first-page":"b702","DOI":"10.1136\/bmj.b702","article-title":"Management of rheumatoid arthritis: summary of NICE guidance","volume":"338","author":"Deighton","year":"2009","journal-title":"BMJ"},{"key":"key2014102715194279_ref1-bib73","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/nri802","article-title":"Development of anti-TNF therapy for rheumatoid arthritis","volume":"2","author":"Feldmann","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"key2014102715194279_ref1-bib74","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/art.1780361206","article-title":"Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha","volume":"36","author":"Elliott","year":"1993","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib75","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"key2014102715194279_ref1-bib76","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.clinthera.2008.11.007","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens","volume":"30","author":"Zintzaras","year":"2008","journal-title":"Clin Ther"},{"key":"key2014102715194279_ref1-bib77","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1365-3083.2009.02296.x","article-title":"A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis","volume":"70","author":"Wiens","year":"2009","journal-title":"Scand J Immunol"},{"key":"key2014102715194279_ref1-bib78","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00296-009-1111-4","article-title":"A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis","volume":"30","author":"Wiens","year":"2010","journal-title":"Rheumatol Int"},{"key":"key2014102715194279_ref1-bib79","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3899\/jrheum.091466","article-title":"Golimumab for rheumatoid arthritis: a systematic review","volume":"37","author":"Singh","year":"2010","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib80","doi-asserted-by":"publisher","first-page":"CD007649","DOI":"10.1002\/14651858.CD007649.pub2","article-title":"Certolizumab pegol (CDP870) for rheumatoid arthritis in adults","volume":"2","author":"Ruiz Garcia","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"key2014102715194279_ref1-bib81","volume-title":"Adalimumab, Etanercept and Infliximab for the Treatment of Rheumatoid Arthritis","author":"","year":"2007"},{"key":"key2014102715194279_ref1-bib82","volume-title":"Certolizumab Pegol for the Treatment of Rheumatoid Arthritis","author":"","year":"2010"},{"key":"key2014102715194279_ref1-bib83","unstructured":"National Institute for Health and Care Excellence. NICE Provisionally Recommends New Drug for Rheumatoid Arthritis. Press release, 13 May 2011. URL: www.nice.org.uk\/media\/E4C\/E5\/2011081GolimumabForRAFAD.pdf (accessed April 2014)."},{"key":"key2014102715194279_ref1-bib84","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1503\/cmaj.091391","article-title":"A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview","volume":"181","author":"Singh","year":"2009","journal-title":"CMAJ"},{"key":"key2014102715194279_ref1-bib85","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2147\/BTT.S36707","article-title":"Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70","volume":"6","author":"Orme","year":"2012","journal-title":"Biologics"},{"key":"key2014102715194279_ref1-bib86","doi-asserted-by":"publisher","first-page":"CD008794","DOI":"10.1002\/14651858.CD008794.pub2","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"2","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"key2014102715194279_ref1-bib87","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1093\/rheumatology\/kem261","article-title":"Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies","volume":"46","author":"Svenson","year":"2007","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib88","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1136\/ard.2008.098467","article-title":"Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide","volume":"68","author":"Strangfeld","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib89","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"key":"key2014102715194279_ref1-bib90","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/rheumatology\/keq169","article-title":"The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis","volume":"49","author":"Lloyd","year":"2010","journal-title":"Rheumatology"},{"issue":"14","key":"key2014102715194279_ref1-bib91","doi-asserted-by":"publisher","DOI":"10.3310\/hta15140","article-title":"Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation","volume":"15","author":"Malottki","year":"2011","journal-title":"Health Technol Assess"},{"key":"key2014102715194279_ref1-bib92","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.semarthrit.2009.12.002","article-title":"Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs","volume":"39","author":"Bergman","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib93","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3899\/jrheum.090074","article-title":"Anakinra for rheumatoid arthritis: a systematic review","volume":"36","author":"Mertens","year":"2009","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib94","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s00296-010-1526-y","article-title":"The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"31","author":"Lee","year":"2011","journal-title":"Rheumatol Int"},{"key":"key2014102715194279_ref1-bib95","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3899\/jrheum.100717","article-title":"Tocilizumab for rheumatoid arthritis: a Cochrane systematic review","volume":"38","author":"Singh","year":"2011","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib96","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3899\/jrheum.091066","article-title":"Abatacept for rheumatoid arthritis: a Cochrane systematic review","volume":"37","author":"Maxwell","year":"2010","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib97","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.2165\/11591480-000000000-00000","article-title":"Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis","volume":"71","author":"Scott","year":"2011","journal-title":"Drugs"},{"key":"key2014102715194279_ref1-bib98","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.berh.2010.02.003","article-title":"Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes","volume":"24","author":"Riese","year":"2010","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"key2014102715194279_ref1-bib99","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.2146\/news120088","article-title":"FDA approves tofacitinib for rheumatoid arthritis","volume":"69","author":"Traynor","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"key2014102715194279_ref1-bib100","first-page":"CD003789","article-title":"Paracetamol versus non-steroidal anti-inflammatory drugs for rheumatoid arthritis","volume":"1","author":"Wienecke","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"key2014102715194279_ref1-bib101","doi-asserted-by":"crossref","DOI":"10.3310\/hta12110","article-title":"Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation","volume":"12","author":"Chen","year":"2008","journal-title":"Health Technol Assess"},{"key":"key2014102715194279_ref1-bib102","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10067-011-1921-0","article-title":"Managing cardiovascular risk in patients with chronic inflammatory diseases","volume":"31","author":"Haraoui","year":"2012","journal-title":"Clin Rheumatol"},{"key":"key2014102715194279_ref1-bib103","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2522\/ptj.20070039","article-title":"Effectiveness of non-pharmacological and nonsurgical interventions for patients with rheumatoid arthritis: an overview of systematic reviews","volume":"87","author":"Christie","year":"2007","journal-title":"Phys Ther"},{"key":"key2014102715194279_ref1-bib104","doi-asserted-by":"publisher","first-page":"CD006853","DOI":"10.1002\/14651858.CD006853.pub2","article-title":"Dynamic exercise programs (aerobic capacity and\/or muscle strength training) in patients with rheumatoid arthritis","volume":"4","author":"Hurkmans","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"key2014102715194279_ref1-bib105","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1136\/ard.2009.123976","article-title":"Evidence for treating rheumatoid arthritis to target: results of a systematic literature search","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib106","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1136\/ard.2011.154179","article-title":"Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire","volume":"70","author":"Haraoui","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib107","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1136\/ard.2010.146662","article-title":"Treating rheumatoid arthritis to target: the patient version of the international recommendations","volume":"70","author":"de Wit","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib108","first-page":"1","article-title":"Treating rheumatoid arthritis to target: evidence-based recommendations for enhanced disease management","volume":"8","author":"Schoels","year":"2012","journal-title":"Rheumatol Clin"},{"key":"key2014102715194279_ref1-bib109","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.rdc.2012.04.004","article-title":"Tight disease control in early RA","volume":"38","author":"Sen","year":"2012","journal-title":"Rheum Dis Clin North Am"},{"key":"key2014102715194279_ref1-bib110","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1002\/art.20350","article-title":"The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis","volume":"50","author":"Welsing","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib111","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"key2014102715194279_ref1-bib112","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1136\/ard.2004.030924","article-title":"Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial","volume":"64","author":"Fransen","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib113","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1136\/ard.2007.071092","article-title":"Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)","volume":"66","author":"Verstappen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib114","doi-asserted-by":"publisher","first-page":"R122","DOI":"10.1186\/ar3060","article-title":"Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial","volume":"12","author":"Rantalaiho","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"key2014102715194279_ref1-bib115","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/rheumatology\/keh464","article-title":"Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)","volume":"44","author":"Ledingham","year":"2005","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib116","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1093\/rheumatology\/ken348","article-title":"Eligibility of rheumatoid arthritis patients for anti-TNF-alpha therapy according to the 2005 recommendations of the French and British Societies for Rheumatology","volume":"47","author":"Fautrel","year":"2008","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib117","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib118","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res"},{"key":"key2014102715194279_ref1-bib119","volume-title":"Guidelines for Prescribing TNF-\u03b1 Blockers in Adults with Rheumatoid Arthritis","author":"","year":"2001"},{"key":"key2014102715194279_ref1-bib120","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/rheumatology\/keq006a","article-title":"BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy","volume":"49","author":"Deighton","year":"2010","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib121","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1007\/s10198-007-0089-7","article-title":"The burden of rheumatoid arthritis and access to treatment: uptake of new therapies","volume":"8","author":"J\u00f6nsson","year":"2008","journal-title":"Eur J Health Econ"},{"key":"key2014102715194279_ref1-bib122","doi-asserted-by":"publisher","first-page":"SR1","DOI":"10.12659\/MSM.881697","article-title":"Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries","volume":"17","author":"Orlewska","year":"2011","journal-title":"Med Sci Monit"},{"key":"key2014102715194279_ref1-bib123","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.healthpol.2011.10.011","article-title":"Do rheumatoid arthritis patients have equal access to treatment with new medicines?: tumour necrosis factor-alpha inhibitors use in four European countries","volume":"104","author":"Hoebert","year":"2012","journal-title":"Health Policy"},{"key":"key2014102715194279_ref1-bib124","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s10198-012-0432-5","article-title":"Patients\u2019 access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries","volume":"14","author":"Laires","year":"2013","journal-title":"Eur J Health Econ"},{"key":"key2014102715194279_ref1-bib125","unstructured":"National Institute for Health and Care Excellence. Assumptions Used in Estimating a Population Benchmark. 16 October 2012. URL: www.nice.org.uk\/usingguidance\/commissioningguides\/biologicaltherapies\/AssumptionsUsedInEstimatingAPopulationBenchmark.jsp (accessed April 2012)."},{"key":"key2014102715194279_ref1-bib126","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1007\/s10067-010-1635-8","article-title":"Introduction to economic modelling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis","volume":"30","author":"Marra","year":"2011","journal-title":"Clin Rheumatol"},{"key":"key2014102715194279_ref1-bib127","doi-asserted-by":"publisher","first-page":"iv10","DOI":"10.1093\/rheumatology\/ker240","article-title":"An overview of models used in economic analyses of biologic therapies for arthritis \u2013 from current diversity to future consensus","volume":"50","author":"Madan","year":"2011","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib128","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/ard.2009.126714","article-title":"Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib129","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/rheumatology\/kem115","article-title":"Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry","volume":"46","author":"Brennan","year":"2007","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib130","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/acr.20338","article-title":"Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review","volume":"63","author":"van der Velde","year":"2011","journal-title":"Arthritis Care Res"},{"key":"key2014102715194279_ref1-bib131","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","article-title":"Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"45","author":"Hyrich","year":"2006","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib132","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1093\/rheumatology\/ken233","article-title":"The importance of the baseline Disease Activity Score 28 in determining responders and non-responders to anti-TNF in UK clinical practice","volume":"47","author":"Smith","year":"2008","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib133","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1684\/ecn.2010.0212","article-title":"Treatment failure with antagonists of TNF-\u03b1: mechanisms and implications for the care of patients","volume":"21","author":"Desroches","year":"2010","journal-title":"Eur Cytokine Netw"},{"key":"key2014102715194279_ref1-bib134","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s00296-011-1838-6","article-title":"Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-\u03b1 therapy","volume":"32","author":"McGeough","year":"2012","journal-title":"Rheumatol Int"},{"key":"key2014102715194279_ref1-bib135","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/rheumatology\/kep331","article-title":"A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis","volume":"49","author":"Ma","year":"2010","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib136","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2217\/ijr.10.44","article-title":"Safety of combination therapies in early RA: a systematic comparison between combination DMARDs and TNF inihibitors with methotrexate","volume":"5","author":"Ma","year":"2010","journal-title":"Int J Clin Rheumatol"},{"key":"key2014102715194279_ref1-bib137","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/rheumatology\/37.6.612","article-title":"Combination therapy in rheumatoid arthritis: updated systematic review","volume":"37","author":"Verhoeven","year":"1998","journal-title":"Br J Rheumatol"},{"issue":"42","key":"key2014102715194279_ref1-bib138","doi-asserted-by":"crossref","DOI":"10.3310\/hta10420","article-title":"A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness","volume":"10","author":"Chen","year":"2006","journal-title":"Health Technol Assess"},{"key":"key2014102715194279_ref1-bib139","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/03009740701607067","article-title":"The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review","volume":"36","author":"Kristensen","year":"2007","journal-title":"Scand J Rheumatol"},{"key":"key2014102715194279_ref1-bib140","doi-asserted-by":"publisher","first-page":"124","DOI":"10.7326\/0003-4819-148-2-200801150-00192","article-title":"Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis","volume":"148","author":"Donahue","year":"2008","journal-title":"Ann Intern Med"},{"key":"key2014102715194279_ref1-bib141","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1136\/ard.2008.099861","article-title":"Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis","volume":"68","author":"Katchamart","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib142","doi-asserted-by":"publisher","first-page":"CD008495","DOI":"10.1002\/14651858.CD008495","article-title":"Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis","volume":"4","author":"Katchamart","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"key2014102715194279_ref1-bib143","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1136\/ard.2009.126573","article-title":"Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA","volume":"69","author":"Nam","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib144","doi-asserted-by":"publisher","first-page":"e30275","DOI":"10.1371\/journal.pone.0030275","article-title":"Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis","volume":"7","author":"Aaltonen","year":"2012","journal-title":"PLoS One"},{"key":"key2014102715194279_ref1-bib145","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/rheumatology\/41.8.899","article-title":"The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database","volume":"41","author":"Scott","year":"2002","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib146","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/rheumatology\/keh140","article-title":"Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis","volume":"43","author":"Strand","year":"2004","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib147","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib148","volume-title":"British National Formulary","author":"","year":"2007"},{"key":"key2014102715194279_ref1-bib149","unstructured":"British Society for Rheumatology. National Guidelines for the Monitoring of Second Line Drugs. July 2000. URL: www.rheumatology.org.uk\/includes\/documents\/cm_docs\/2009\/m\/monitoring_second_line_drugs.pdf (accessed August 2014)."},{"key":"key2014102715194279_ref1-bib150","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1093\/rheumatology\/kel216a","article-title":"BSR\/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists","volume":"47","author":"Chakravarty","year":"2008","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib151","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1093\/rheumatology\/keq249a","article-title":"BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies","volume":"49","author":"Ding","year":"2010","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib152","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1053\/berh.2000.0106","article-title":"Quality of life measures: use and abuse","volume":"14","author":"Scott","year":"2000","journal-title":"Baillieres Best Pract Res Clin Rheumatol"},{"key":"key2014102715194279_ref1-bib153","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-7525-1-20","article-title":"The Stanford Health Assessment Questionnaire: dimensions and practical applications","volume":"1","author":"Bruce","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"key2014102715194279_ref1-bib154","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1002\/1529-0131(200012)43:12<2751::AID-ANR15>3.0.CO;2-6","article-title":"A reappraisal of HAQ disability in rheumatoid arthritis","volume":"43","author":"Wolfe","year":"2000","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib155","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol \u2013 a new facility for the measurement of health-related quality of life","volume":"16","author":"","year":"1990","journal-title":"Health Policy"},{"key":"key2014102715194279_ref1-bib156","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","article-title":"SF-36 health survey update","volume":"25","author":"Ware","year":"2000","journal-title":"Spine"},{"key":"key2014102715194279_ref1-bib157","first-page":"S218","article-title":"Health-related quality of life \u2013 an introduction","volume":"13","author":"Khanna","year":"2007","journal-title":"Am J Manag Care"},{"key":"key2014102715194279_ref1-bib158","first-page":"1528","article-title":"Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D, RAQoL, and HAQ in patients with rheumatoid arthritis","volume":"35","author":"Linde","year":"2008","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib159","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3899\/jrheum.090778","article-title":"EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia","volume":"37","author":"Wolfe","year":"2010","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib160","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/1477-7525-9-99","article-title":"Measurement properties of physical function scales validated for use in patients with rheumatoid arthritis: a systematic review of the literature","volume":"9","author":"Oude Voshaar","year":"2011","journal-title":"Health Qual Life Outcomes"},{"key":"key2014102715194279_ref1-bib161","first-page":"S20","article-title":"Joint damage and disability in rheumatoid arthritis: an updated systematic review","volume":"21","author":"Scott","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"key2014102715194279_ref1-bib162","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/028418517701800415","article-title":"Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films","volume":"8","author":"Larsens","year":"1977","journal-title":"Acta Radiol Diagn"},{"key":"key2014102715194279_ref1-bib163","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/rheumatology\/34.1.56","article-title":"Proposed modification to Larsen\u2019s scoring methods for hand and wrist radiographs","volume":"34","author":"Scott","year":"1995","journal-title":"Br J Rheumatol"},{"key":"key2014102715194279_ref1-bib164","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with RA","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib165","first-page":"2037","article-title":"Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update","volume":"32","author":"Lassere","year":"2005","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib166","unstructured":"European Medicines Agency. Guideline on Clinical Investigation of Medicinal Products other than NSAIDs for Treatment of Rheumatoid Arthritis. 2011. URL: www.ema.europa.eu\/ema\/index.jsp (accessed April 2014)."},{"key":"key2014102715194279_ref1-bib167","unstructured":"US Food and Drug Administration. Guidance for Industry. Rheumatoid Arthritis: Developing Drug Products for Treatment. 2013. URL: www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm (accessed April 2014)."},{"key":"key2014102715194279_ref1-bib168","first-page":"203","volume-title":"Measuring Mental Health Needs","author":"Beecham","year":"1992"},{"key":"key2014102715194279_ref1-bib169","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/acr.20642","article-title":"Long-term outcomes and costs of an integrated rehabilitation program for chronic knee pain: a pragmatic, cluster randomized, controlled trial","volume":"64","author":"Hurley","year":"2012","journal-title":"Arthritis Care Res"},{"key":"key2014102715194279_ref1-bib170","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"key2014102715194279_ref1-bib171","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1136\/ard.2007.076299","article-title":"Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis","volume":"67","author":"Choy","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib172","first-page":"557","article-title":"Minimum important difference between patients with rheumatoid arthritis: the patient\u2019s perspective","volume":"20","author":"Wells","year":"1993","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib173","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1001\/archinte.1993.00410110045008","article-title":"Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology","volume":"153","author":"Redelmeier","year":"1993","journal-title":"Arch Intern Med"},{"key":"key2014102715194279_ref1-bib174","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M","article-title":"Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis","volume":"43","author":"Kosinski","year":"2000","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib175","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1002\/1529-0131(199909)42:9<1870::AID-ANR11>3.0.CO;2-D","article-title":"Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group","volume":"42","author":"Strand","year":"1999","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib176","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"key2014102715194279_ref1-bib177","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/biomet\/63.3.581","article-title":"Inference and missing data","volume":"63","author":"Rubin","year":"1976","journal-title":"Biometrika"},{"key":"key2014102715194279_ref1-bib178","doi-asserted-by":"crossref","DOI":"10.1002\/9781119013563","volume-title":"Statistical Analysis with Missing Data","author":"Little","year":"2002","edition":"2nd edn."},{"key":"key2014102715194279_ref1-bib179","doi-asserted-by":"crossref","DOI":"10.1201\/9781439821862","volume-title":"Analysis of Incomplete Multivariate Data","author":"Schafer","year":"1997","edition":"1st edn."},{"key":"key2014102715194279_ref1-bib180","volume-title":"R: A language and environment for statistical computing","author":"","year":"2012"},{"key":"key2014102715194279_ref1-bib181","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1467-9876.2007.00590.x","article-title":"Analysis of longitudinal data with drop-out: objectives, assumptions and a proposal","volume":"56","author":"Diggle","year":"2007","journal-title":"J R Stat Soc C Appl Stat"},{"key":"key2014102715194279_ref1-bib182","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","article-title":"The estimation of a preference-based measure of health from the SF-36","volume":"21","author":"Brazier","year":"2002","journal-title":"J Health Econ"},{"key":"key2014102715194279_ref1-bib183","volume-title":"A Social Tariff for EuroQol: Results from a UK Population Survey","author":"Dolan","year":"1995"},{"key":"key2014102715194279_ref1-bib184","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/hec.944","article-title":"Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility","volume":"14","author":"Manca","year":"2005","journal-title":"Health Econ"},{"key":"key2014102715194279_ref1-bib185","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/S0140-6736(00)02039-0","article-title":"Subgroup analysis and other (mis)uses of baseline data in clinical trials","volume":"355","author":"Assmann","year":"2000","journal-title":"Lancet"},{"key":"key2014102715194279_ref1-bib186","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/(SICI)1099-1050(199905)8:3<257::AID-HEC427>3.0.CO;2-E","article-title":"A Bayesian approach to stochastic cost-effectiveness analysis","volume":"8","author":"Briggs","year":"1999","journal-title":"Health Econ"},{"key":"key2014102715194279_ref1-bib187","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"key2014102715194279_ref1-bib188","volume-title":"Methods Guide for Comparative Effectiveness Review","author":"Viswanathan","year":"2012"},{"key":"key2014102715194279_ref1-bib189","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"key2014102715194279_ref1-bib190","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<841::AID-SIM781>3.0.CO;2-D","article-title":"Detecting and describing heterogeneity in meta-analysis","volume":"17","author":"Hardy","year":"1998","journal-title":"Stat Med"},{"key":"key2014102715194279_ref1-bib191","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"key2014102715194279_ref1-bib192","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1093\/rheumatology\/36.10.1082","article-title":"Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial","volume":"36","author":"Haagsma","year":"1997","journal-title":"Br J Rheumatol"},{"key":"key2014102715194279_ref1-bib193","first-page":"1493","article-title":"Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine","volume":"25","author":"van den Borne","year":"1998","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib194","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/ard.58.4.220","article-title":"Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components","volume":"58","author":"Dougados","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib195","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/S0140-6736(98)08513-4","article-title":"Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group","volume":"353","author":"Mottonen","year":"1999","journal-title":"Lancet"},{"key":"key2014102715194279_ref1-bib196","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/1529-0131(200008)43:8<1809::AID-ANR17>3.0.CO;2-D","article-title":"Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone","volume":"43","author":"Proudman","year":"2000","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib197","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/rheumatology\/41.8.892","article-title":"Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years","volume":"41","author":"Ferraccioli","year":"2002","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib198","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1136\/ard.62.4.291","article-title":"Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis","volume":"62","author":"Gerards","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib199","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1093\/rheumatology\/keg394","article-title":"Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone","volume":"42","author":"Marchesoni","year":"2003","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib200","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1136\/ard.2003.014050","article-title":"Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial","volume":"63","author":"Capell","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib201","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.arcmed.2003.07.008","article-title":"A randomized, double-blind, multicenter, controlled clinical trial of cyclosporine plus chloroquine vs. cyclosporine plus placebo in early-onset rheumatoid arthritis","volume":"35","author":"Miranda","year":"2004","journal-title":"Arch Med Res"},{"key":"key2014102715194279_ref1-bib202","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3109\/s10165-005-0420-z","article-title":"Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study","volume":"15","author":"Ichikawa","year":"2005","journal-title":"Mod Rheumatol"},{"key":"key2014102715194279_ref1-bib203","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00296-003-0384-2","article-title":"An open, randomized comparison study of cyclosporine A, cyclosporine A\u2009+\u2009methotrexate and cyclosporine A\u2009+\u2009hydroxychloroquine in the treatment of early severe rheumatoid arthritis","volume":"25","author":"Sarzi-Puttini","year":"2005","journal-title":"Rheumatol Int"},{"key":"key2014102715194279_ref1-bib204","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1002\/art.21298","article-title":"Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial","volume":"52","author":"Svensson","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib205","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1002\/art.21421","article-title":"Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial","volume":"52","author":"Wassenberg","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib206","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/art.21796","article-title":"Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study","volume":"54","author":"Hetland","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib207","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/art.21620","article-title":"Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone","volume":"54","author":"O\u2019Dell","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib208","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/ard.2003.013961","article-title":"Infliximab in active early rheumatoid arthritis","volume":"63","author":"Breedveld","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib209","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"St Clair","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib210","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/art.20123","article-title":"Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis","volume":"50","author":"Taylor","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib211","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/art.20712","article-title":"Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial","volume":"52","author":"Quinn","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib212","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib213","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1002\/art.23055","article-title":"Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone","volume":"56","author":"Durez","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib214","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","article-title":"Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial","volume":"372","author":"Emery","year":"2008","journal-title":"Lancet"},{"key":"key2014102715194279_ref1-bib215","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/rheumatology\/kep261","article-title":"Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial","volume":"48","author":"Soubrier","year":"2009","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib216","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/annrheumdis-2012-201612","article-title":"Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study","volume":"72","author":"Detert","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib217","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/annrheumdis-2011-201247","article-title":"Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study","volume":"72","author":"Kavanaugh","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib218","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0140-6736(09)60944-2","article-title":"Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial","volume":"374","author":"van Vollenhoven","year":"2009","journal-title":"Lancet"},{"key":"key2014102715194279_ref1-bib219","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1002\/art.34498","article-title":"TEAR Investigators. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial","volume":"64","author":"Moreland","year":"2012","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib220","doi-asserted-by":"publisher","first-page":"406","DOI":"10.7326\/0003-4819-146-6-200703200-00005","article-title":"Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial","volume":"146","author":"Goekoop-Ruiterman","year":"2007","journal-title":"Ann Intern Med"},{"key":"key2014102715194279_ref1-bib221","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/S0140-6736(12)60027-0","article-title":"Swefot study group. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial","volume":"379","author":"van Vollenhoven","year":"2012","journal-title":"Lancet"},{"key":"key2014102715194279_ref1-bib222","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3109\/03009749409103721","article-title":"Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. A multicenter randomized placebo-controlled trial","volume":"23","author":"Ferraz","year":"1994","journal-title":"Scand J Rheumatol"},{"key":"key2014102715194279_ref1-bib223","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1002\/art.1780381213","article-title":"Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment","volume":"38","author":"Willkens","year":"1995","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib224","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/rheumatology\/35.11.1142","article-title":"Adding low-dose cyclosporin A to parenteral gold therapy in rheumatoid arthritis: a double-blind placebo-controlled study","volume":"35","author":"Bendix","year":"1996","journal-title":"Br J Rheumatol"},{"key":"key2014102715194279_ref1-bib225","doi-asserted-by":"publisher","first-page":"726","DOI":"10.7326\/0003-4819-137-9-200211050-00007","article-title":"Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial","volume":"137","author":"Kremer","year":"2002","journal-title":"Ann Intern Med"},{"key":"key2014102715194279_ref1-bib226","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1136\/ard.2003.016709","article-title":"When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?","volume":"64","author":"Dougados","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib227","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/art.21018","article-title":"A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study","volume":"52","author":"Lehman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib228","first-page":"486","article-title":"Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis","volume":"33","author":"Karanikolas","year":"2006","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib229","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/ard.2006.057133","article-title":"Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study","volume":"66","author":"Capell","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib230","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"key2014102715194279_ref1-bib231","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib232","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"key2014102715194279_ref1-bib233","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/art.23383","article-title":"Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study","volume":"58","author":"Kay","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib234","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1002\/art.23964","article-title":"Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"58","author":"Keystone","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib235","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1136\/ard.2008.101659","article-title":"Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial","volume":"68","author":"Smolen","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib236","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/art.27348","article-title":"Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study","volume":"62","author":"Kremer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib237","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1303006","article-title":"Therapies for active rheumatoid arthritis after methotrexate failure","volume":"369","author":"O\u2019Dell","year":"2013","journal-title":"N Engl J Med"},{"key":"key2014102715194279_ref1-bib238","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/art.21655","article-title":"Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib239","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/rheumatology\/kes082","article-title":"Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial","volume":"51","author":"Keystone","year":"2012","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib240","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S0895-4356(97)00068-1","article-title":"Assessing non-consent bias with parallel randomized and nonrandomized clinical trials","volume":"50","author":"Marcus","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"key2014102715194279_ref1-bib241","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/10543406.2011.550107","article-title":"Intent-to-randomize corrections for missing data resulting from run-in selection bias in clinical trials for chronic conditions","volume":"21","author":"Berger","year":"2011","journal-title":"J Biopharm Stat"},{"key":"key2014102715194279_ref1-bib242","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1136\/ard.2004.030908","article-title":"A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs","volume":"64","author":"Choy","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib243","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1002\/art.22052","article-title":"Measuring function in rheumatoid arthritis: identifying reversible and irreversible components","volume":"54","author":"Aletaha","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib244","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1136\/ard.2007.071415","article-title":"Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results","volume":"67","author":"Aletaha","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib245","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1093\/biostatistics\/kxq041","article-title":"A multistate model for events defined by prolonged observation","volume":"12","author":"Farewell","year":"2011","journal-title":"Biostatistics"},{"key":"key2014102715194279_ref1-bib246","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1093\/rheumatology\/35.6.574","article-title":"Are we making the most of the Stanford Health Assessment Questionnaire?","volume":"35","author":"Tennant","year":"1996","journal-title":"Br J Rheumatol"},{"key":"key2014102715194279_ref1-bib247","first-page":"982","article-title":"Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2,491 rheumatoid arthritis patients following leflunomide initiation","volume":"28","author":"Wolfe","year":"2001","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib248","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1053\/berh.2000.0106","article-title":"Quality of life measures: use and abuse","volume":"14","author":"Scott","year":"2000","journal-title":"Baillieres Best Pract Res Clin Rheumatol"},{"key":"key2014102715194279_ref1-bib249","first-page":"S43","article-title":"The consequences of rheumatoid arthritis: quality of life measures in the individual patient","volume":"23","author":"Pollard","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"key2014102715194279_ref1-bib250","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3899\/jrheum.080479","article-title":"The minimally important difference for the Health Assessment Questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials","volume":"36","author":"Pope","year":"2009","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib251","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/ard.43.1.8","article-title":"Progression of radiological changes in rheumatoid arthritis","volume":"43","author":"Scott","year":"1984","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib252","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/BF00272436","article-title":"Progressive joint damage during penicillamine therapy for rheumatoid arthritis","volume":"8","author":"Scott","year":"1988","journal-title":"Rheumatol Int"},{"key":"key2014102715194279_ref1-bib253","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/rheumatology\/29.2.126","article-title":"Radiological progression in rheumatoid arthritis: do D-penicillamine and hydroxychloroquine have different effects?","volume":"29","author":"Scott","year":"1990","journal-title":"Br J Rheumatol"},{"key":"key2014102715194279_ref1-bib254","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/art.1780310124","article-title":"The effect of lymphoid irradiation on the progression of joint damage in intractable rheumatoid arthritis","volume":"31","author":"Scott","year":"1988","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib255","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/anr.1780320503","article-title":"Lymphoid irradiation in intractable rheumatoid arthritis. Long-term follow-up of patients treated with 750 rads or 2000 rads","volume":"32","author":"Soden","year":"1989","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib256","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/BF00541231","article-title":"The assessment of radiological changes in the hands and wrists in rheumatoid arthritis","volume":"3","author":"Grindulis","year":"1983","journal-title":"Rheumatol Int"},{"key":"key2014102715194279_ref1-bib257","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/rheumatology\/24.1.31","article-title":"Methods of X-ray assessment in rheumatoid arthritis: a re-evaluation","volume":"24","author":"Scott","year":"1985","journal-title":"Br J Rheumatol"},{"key":"key2014102715194279_ref1-bib258","first-page":"740","article-title":"Introduction to reading radiographs by the Scott modification of the Larsen method","volume":"26","author":"Edmonds","year":"1999","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib259","first-page":"1288","article-title":"Reference curves of radiographic damage in patients with rheumatoid arthritis: application of quantile regression and fractional polynomials","volume":"24","author":"Lassere","year":"1997","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib260","first-page":"S53","article-title":"The radiological assessment of rheumatoid arthritis","volume":"15","author":"Scott","year":"1997","journal-title":"Clin Exp Rheumatol"},{"issue":"34","key":"key2014102715194279_ref1-bib261","doi-asserted-by":"crossref","DOI":"10.3310\/hta9340","article-title":"The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis","volume":"9","author":"Symmons","year":"2005","journal-title":"Health Technol Assess"},{"key":"key2014102715194279_ref1-bib262","volume-title":"EULAR Handbook of Clinical Assessment in Rheumatoid Arthritis","author":"van Riel","year":"2000"},{"key":"key2014102715194279_ref1-bib263","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/rheumatology\/keg235","article-title":"Joint counts in routine practice","volume":"42","author":"Scott","year":"2003","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib264","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/BF02238547","article-title":"Standardising joint assessment in rheumatoid arthritis","volume":"15","author":"Scott","year":"1996","journal-title":"Clin Rheumatol"},{"key":"key2014102715194279_ref1-bib265","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3899\/jrheum.111224","article-title":"Does a joint count calibration exercise make a difference? Implications for clinical trials and training","volume":"39","author":"Stamp","year":"2012","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib266","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/rheumatology\/keq209","article-title":"Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumor necrosis factor therapy for rheumatoid arthritis between 2001 and 2008","volume":"50","author":"Hyrich","year":"2011","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib267","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1136\/annrheumdis-2011-150573","article-title":"A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry","volume":"71","author":"Greenberg","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib268","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/art.27227","article-title":"Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib269","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1093\/rheumatology\/kes078","article-title":"The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry","volume":"51","author":"de Punder","year":"2012","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib270","first-page":"1670","article-title":"Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study","volume":"34","author":"Mancarella","year":"2007","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib271","doi-asserted-by":"publisher","first-page":"R66","DOI":"10.1186\/ar1933","article-title":"Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low \u2013 results from RABBIT, the German biologics register","volume":"8","author":"Listing","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"key2014102715194279_ref1-bib272","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1258\/135581904322987535","article-title":"Modelling in the economic evaluation of health care: selecting the appropriate approach","volume":"9","author":"Barton","year":"2004","journal-title":"J Health Serv Res Policy"},{"key":"key2014102715194279_ref1-bib273","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1056\/NEJMe1306381","article-title":"Making rational treatment decisions in rheumatoid arthritis when methotrexate fails","volume":"369","author":"Bathon","year":"2013","journal-title":"N Engl J Med"},{"key":"key2014102715194279_ref1-bib274","doi-asserted-by":"publisher","first-page":"iv21","DOI":"10.1093\/rheumatology\/kes088","article-title":"Economic benefits of optimizing anchor therapy for rheumatoid arthritis","volume":"51","author":"Fautrel","year":"2012","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib275","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1002\/art.10471","article-title":"Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis","volume":"46","author":"Kobelt","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib276","first-page":"1709","article-title":"Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone","volume":"31","author":"Korthals-de Bos","year":"2004","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib277","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/rheumatology\/37.10.1102","article-title":"Cost-effectiveness and cost\u2013utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone","volume":"37","author":"Verhoeven","year":"1998","journal-title":"Br J Rheumatol"},{"key":"key2014102715194279_ref1-bib278","doi-asserted-by":"publisher","first-page":"329","DOI":"10.7326\/0003-4819-156-5-201203060-00004","article-title":"Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial","volume":"156","author":"Bakker","year":"2012","journal-title":"Ann Intern Med"},{"key":"key2014102715194279_ref1-bib279","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1002\/1529-0131(200010)43:10<2316::AID-ANR20>3.0.CO;2-6","article-title":"A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis","volume":"43","author":"Choi","year":"2000","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib280","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3899\/jrheum.101327","article-title":"Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis","volume":"38","author":"Tosh","year":"2011","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib281","first-page":"CD002047","article-title":"Leflunomide for treating rheumatoid arthritis","volume":"1","author":"Osiri","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"key2014102715194279_ref1-bib282","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/rheumatology\/keh057","article-title":"The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapy","volume":"43","author":"Bingham","year":"2004","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib283","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/ar2555","article-title":"Randomized controlled trial design in rheumatoid arthritis: the past decade","volume":"11","author":"Strand","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"key2014102715194279_ref1-bib284","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJM200006223422507","article-title":"Randomized, controlled trials, observational studies, and the hierarchy of research designs","volume":"342","author":"Concato","year":"2000","journal-title":"N Engl J Med"},{"key":"key2014102715194279_ref1-bib285","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1136\/ard.2007.072447","article-title":"The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice","volume":"66","author":"Kievit","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib286","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/ar1170","article-title":"Equipoise, design bias, and randomized controlled trials: the elusive ethics of new drug development","volume":"6","author":"Fries","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"key2014102715194279_ref1-bib287","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1136\/bmj.326.7396.980","article-title":"Ethics of clinical trials from a Bayesian and decision analytic perspective: whose equipoise is it anyway?","volume":"326","author":"Lilford","year":"2003","journal-title":"BMJ"},{"key":"key2014102715194279_ref1-bib288","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(00)02605-2","article-title":"The uncertainty principle and industry-sponsored research","volume":"356","author":"Djulbegovic","year":"2000","journal-title":"Lancet"},{"key":"key2014102715194279_ref1-bib289","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/ar1189","article-title":"A surplus of positive trials: weighing biases and reconsidering equipoise","volume":"6","author":"Felson","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"key2014102715194279_ref1-bib290","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/ar1442","article-title":"Ethics of randomised controlled trials \u2013 not yet time to give up on equipoise","volume":"6","author":"Ashcroft","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"key2014102715194279_ref1-bib291","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S0006-3223(01)01223-9","article-title":"Strengthening clinical effectiveness trials: equipoise-stratified randomization","volume":"50","author":"Lavori","year":"2001","journal-title":"Biol Psychiatry"},{"key":"key2014102715194279_ref1-bib292","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1093\/rheumatology\/kel132","article-title":"Patients\u2019 views on the quality of health care for rheumatoid arthritis","volume":"45","author":"Lempp","year":"2006","journal-title":"Rheumatology"},{"key":"key2014102715194279_ref1-bib293","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/17423953060020020601","article-title":"The personal impact of rheumatoid arthritis on patients\u2019 identity","volume":"2","author":"Lempp","year":"2006","journal-title":"Chronic Illn"},{"key":"key2014102715194279_ref1-bib294","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/1471-2474-13-200","article-title":"Patients\u2019 views about treatment with combination therapy for rheumatoid arthritis: a comparative qualitative study","volume":"13","author":"Lempp","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"key":"key2014102715194279_ref1-bib295","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/ard.2010.135376","article-title":"The need for personalised medicine for rheumatoid arthritis","volume":"70","author":"Isaacs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib296","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1136\/ard.2011.154252","article-title":"Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies","volume":"70","author":"Miossec","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib297","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1136\/ard.2010.146043","article-title":"Changes in patient characteristics in anti-tumor necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years","volume":"70","author":"Rahman","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key2014102715194279_ref1-bib298","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/art.10817","article-title":"Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis","volume":"48","author":"Sokka","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib299","first-page":"1138","article-title":"Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission","volume":"30","author":"Sokka","year":"2003","journal-title":"J Rheumatol"},{"key":"key2014102715194279_ref1-bib300","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.1002\/art.22193","article-title":"Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials","volume":"54","author":"Zink","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key2014102715194279_ref1-bib301","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/jama.290.12.1624","article-title":"Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy","volume":"290","author":"Tunis","year":"2003","journal-title":"JAMA"},{"key":"key2014102715194279_ref1-bib302","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1136\/bmj.39281.615706.94","article-title":"How can we regulate medicines better?","volume":"335","author":"Garattini","year":"2007","journal-title":"BMJ"},{"key":"key2014102715194279_ref1-bib303","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1056\/NEJMp0906490","article-title":"New, but not improved? Incorporating comparative-effectiveness information into FDA labeling","volume":"361","author":"Stafford","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta18660\/hta18660.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002095","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta18660\/hta18660.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:34:16Z","timestamp":1692113656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta18660\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":303,"journal-issue":{"issue":"66","published-online":{"date-parts":[[2014,10]]}},"alternative-id":["10.3310\/hta18660"],"URL":"https:\/\/doi.org\/10.3310\/hta18660","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}